Please use this identifier to cite or link to this item:
https://ir.swu.ac.th/jspui/handle/123456789/12175
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wudhikarn K. | |
dc.contributor.author | Bunworasate U. | |
dc.contributor.author | Julamanee J. | |
dc.contributor.author | Lekhakula A. | |
dc.contributor.author | Ekwattanakit S. | |
dc.contributor.author | Khuhapinant A. | |
dc.contributor.author | Chuncharunee S. | |
dc.contributor.author | Niparuck P. | |
dc.contributor.author | Numbenjapon T. | |
dc.contributor.author | Prayongratana K. | |
dc.contributor.author | Kanitsap N. | |
dc.contributor.author | Wongkhantee S. | |
dc.contributor.author | Makruasi N. | |
dc.contributor.author | Wong P. | |
dc.contributor.author | Norasetthada L. | |
dc.contributor.author | Nawarawong W. | |
dc.contributor.author | Sirijerachai C. | |
dc.contributor.author | Chansung K. | |
dc.contributor.author | Suwanban T. | |
dc.contributor.author | Praditsuktavorn P. | |
dc.contributor.author | Intragumtornchai T. | |
dc.contributor.author | on behalf of Thai Lymphoma Study Group | |
dc.date.accessioned | 2021-04-05T03:02:05Z | - |
dc.date.available | 2021-04-05T03:02:05Z | - |
dc.date.issued | 2020 | |
dc.identifier.issn | 18794068 | |
dc.identifier.other | 2-s2.0-85063582476 | |
dc.identifier.uri | https://ir.swu.ac.th/jspui/handle/123456789/12175 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063582476&doi=10.1016%2fj.jgo.2019.03.016&partnerID=40&md5=3ef0840820bce919d55b06f2fc54bb86 | |
dc.description.abstract | Introduction: Peripheral T cell NHL (PTCL) and natural killer/T cell NHL (NKTCL) are relatively rare disorders. Data on clinical presentation, treatment and outcome are limited especially in older age groups. Methods: We identified 127 patients with PTCL and NKTCL, excluding cutaneous T/NK cell lymphoma, aged over 60 years old from Thailand nationwide multicenter registry. Results: Of 127 patients, median age of diagnosis was 67 years old. Patients aged older than 75 years old had similar characteristics to younger (60–74 years old) but higher comorbidity index. Seventy-nine patients (62.2%) received intensive/definite multi-agent chemotherapy, however, the proportion was significant lower in older patients (70.4% vs 34.5%, p <. 001). After a median follow up duration of 17.3 months, 2-year progression free survival and overall survival were 38.1% and 48.5%. Univariate and multivariable analysis demonstrated older age, poor performance status and absence of definite multi-agent chemotherapy were associated with inferior survival. Definite multi-agent lymphoma specific chemotherapy was an independent factor for overall survival after adjustment for age, comorbidity index, performance status and prognostic index for T cell lymphoma. Conclusion: Despite overall poor prognosis of PTCL and NKTCL in older adults, chemotherapy could result in objective response and long-term survival in selected patients of this vulnerable age group thus emphasizing the importance of comprehensive geriatric evaluation. © 2019 | |
dc.subject | asparaginase | |
dc.subject | cyclophosphamide | |
dc.subject | dexamethasone | |
dc.subject | doxorubicin | |
dc.subject | etoposide | |
dc.subject | ifosfamide | |
dc.subject | methotrexate | |
dc.subject | prednisolone | |
dc.subject | steroid | |
dc.subject | vincristine | |
dc.subject | adult | |
dc.subject | aged | |
dc.subject | aging | |
dc.subject | Article | |
dc.subject | cancer chemotherapy | |
dc.subject | cancer combination chemotherapy | |
dc.subject | cancer prognosis | |
dc.subject | cancer radiotherapy | |
dc.subject | cancer registry | |
dc.subject | cohort analysis | |
dc.subject | comorbidity | |
dc.subject | controlled study | |
dc.subject | diarrhea | |
dc.subject | drug dose escalation | |
dc.subject | drug fatality | |
dc.subject | drug safety | |
dc.subject | febrile neutropenia | |
dc.subject | female | |
dc.subject | follow up | |
dc.subject | geriatric assessment | |
dc.subject | groups by age | |
dc.subject | human | |
dc.subject | ileus | |
dc.subject | infection | |
dc.subject | intensive care | |
dc.subject | long term survival | |
dc.subject | major clinical study | |
dc.subject | male | |
dc.subject | multiple cycle treatment | |
dc.subject | neuropathy | |
dc.subject | neutropenia | |
dc.subject | NK T cell lymphoma | |
dc.subject | nonhodgkin lymphoma | |
dc.subject | oral mucositis | |
dc.subject | overall survival | |
dc.subject | peripheral T cell lymphoma | |
dc.subject | physical performance | |
dc.subject | polypharmacy | |
dc.subject | priority journal | |
dc.subject | progression free survival | |
dc.subject | Thailand | |
dc.subject | thrombocytopenia | |
dc.subject | treatment outcome | |
dc.title | Characteristics, treatment patterns, prognostic determinants and outcome of peripheral T cell lymphoma and natural killer/T cell non-Hodgkin Lymphoma in older patients: The result of the nationwide multi-institutional registry Thai Lymphoma Study Group | |
dc.type | Article | |
dc.rights.holder | Scopus | |
dc.identifier.bibliograpycitation | Journal of Geriatric Oncology. Vol 11, No.1 (2020), p.62-68 | |
dc.identifier.doi | 10.1016/j.jgo.2019.03.016 | |
Appears in Collections: | Scopus 1983-2021 |
Files in This Item:
There are no files associated with this item.
Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.